These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15671919)

  • 41. Angiotensin-converting enzyme inhibitors: mechanisms of action and implications in anesthesia practice.
    Behnia R; Molteni A; Igić R
    Curr Pharm Des; 2003; 9(9):763-76. PubMed ID: 12570793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin II subtype 1 receptor blockers and renal function.
    Toto R
    Arch Intern Med; 2001 Jun; 161(12):1492-9. PubMed ID: 11427096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The renin-angiotensin system in the pathophysiology of type 2 diabetes.
    Goossens GH
    Obes Facts; 2012; 5(4):611-24. PubMed ID: 22986649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potassium as a link between insulin and the renin-angiotensin-aldosterone system.
    Ferrannini E; Galvan AQ; Santoro D; Natali A
    J Hypertens Suppl; 1992 Apr; 10(1):S5-10. PubMed ID: 1619503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
    Bălută M; Vintilă V; Vintilă M
    Rom J Intern Med; 2004; 42(2):277-88. PubMed ID: 15529618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The intracellular renin-angiotensin system in the heart.
    Kumar R; Singh VP; Baker KM
    Curr Hypertens Rep; 2009 Apr; 11(2):104-10. PubMed ID: 19278599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
    Verdecchia P; Angeli F; Mazzotta G; Ambrosio G; Reboldi G
    Curr Vasc Pharmacol; 2010 Nov; 8(6):742-6. PubMed ID: 20626343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension.
    Contreras F; de la Parte MA; Cabrera J; Ospino N; Israili ZH; Velasco M
    Am J Ther; 2003; 10(6):401-8. PubMed ID: 14624277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes.
    Nosadini R; Tonolo G
    Nutr Metab Cardiovasc Dis; 2004 Apr; 14(2):88-93. PubMed ID: 15242241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renin angiotensin system inhibition attenuates adipocyte-breast cancer cell interactions.
    Rasha F; Ramalingam L; Menikdiwela K; Hernandez A; Moussa H; Gollahon L; Layeequr Rahman R; Moustaid-Moussa N
    Exp Cell Res; 2020 Sep; 394(1):112114. PubMed ID: 32504676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renin-angiotensin system inhibition is associated with reduced risk of left atrial appendage thrombosis formation in patients with atrial fibrillation.
    Suo Y; Zhang Y; Wang Y; Yuan M; Kariyawasam S; Tse G; Liu T; Fu H; Li G
    Cardiol J; 2018; 25(5):611-620. PubMed ID: 28980280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
    Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blockade of the renin-angiotensin system.
    Nicholls MG; Charles CJ; Crozier IG; Espiner EA; Ikram H; Rademaker MJ; Richards AM; Yandle TG
    J Hypertens Suppl; 1994 Dec; 12(10):S95-103. PubMed ID: 7769497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [RAAS and insulin resistance].
    Motoshima H; Araki E
    Nihon Rinsho; 2012 Sep; 70(9):1542-9. PubMed ID: 23012801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.